The oral KIF11 inhibitor 4SC-205 exhibits antitumor activity and potentiates standard and targeted therapies in primary and metastatic neuroblastoma models

Masanas Jimenez, Marc; Masia Fandos, Nuria; Suarez Cabrera, Leticia; Olivan Riera, Mireia; Soriano Fernández, Aroa; Majem Cavaller, Blanca; Jimenez Jimenez, Carlos Gonzalo; Boloix Amenós, Ariadna; Toledano Martin, Ignasi; Navarro Jimenez, Alexandra; Sánchez de Toledo Codina, Josep; Roma Castanyer, Josep; Moreno Martín-Retortillo, Lucas; Gallego Melcón, Soledad; Santamaria Margalef, Anna; Segura Ginard, Miguel; Guillén Burrieza, Gabriela

View

The oral KIF11 inhibitor 4SC-205 exhibits antitumor activity and potentiates standard and targeted therapies in primary and metastatic neuroblastoma models, 2021 (2.287Mb)

The oral KIF11 inhibitor 4SC-205 exhibits antitumor activity and potentiates standard and targeted therapies in primary and metastatic neuroblastoma models, 2021. Material suplementari (2.688Mb)

Date

2021-10

Author

Masanas Jimenez, Marc

Masia Fandos, Nuria

Suarez Cabrera, Leticia

Olivan Riera, Mireia

Soriano Fernández, Aroa

Majem Cavaller, Blanca

Jimenez Jimenez, Carlos Gonzalo

Boloix Amenós, Ariadna

Toledano Martin, Ignasi

Navarro Jimenez, Alexandra

Sánchez de Toledo Codina, Josep

Roma Castanyer, Josep

Moreno Martín-Retortillo, Lucas

Gallego Melcón, Soledad

Santamaria Margalef, Anna

Segura Ginard, Miguel

Guillén Burrieza, Gabriela

Show full item record

Abstract

In summary, our study provides a rationale for the future therapeutic integration in clinical trials of 4SC-205, an structurally distinct oral KIF11 inhibitor that shows potent antitumor activity in multiple preclinical neuroblastoma models and sensitizes neuroblastoma cells to standard chemotherapy and specific neuroblastoma-targeted therapies.

Keywords

KIF11 inhibitor; Targeted therapies; Metastasis

Bibliographic citation

Masanas M, Masiá N, Suárez-Cabrera L, Olivan M, Soriano A, Majem B, et al. The oral KIF11 inhibitor 4SC-205 exhibits antitumor activity and potentiates standard and targeted therapies in primary and metastatic neuroblastoma models. Clin Transl Med. 2021 Oct;11(10):e533.